Literature DB >> 19474385

Cancer statistics, 2009.

Ahmedin Jemal1, Rebecca Siegel, Elizabeth Ward, Yongping Hao, Jiaquan Xu, Michael J Thun.   

Abstract

Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. Incidence and death rates are standardized by age to the 2000 United States standard million population. A total of 1,479,350 new cancer cases and 562,340 deaths from cancer are projected to occur in the United States in 2009. Overall cancer incidence rates decreased in the most recent time period in both men (1.8% per year from 2001 to 2005) and women (0.6% per year from 1998 to 2005), largely because of decreases in the three major cancer sites in men (lung, prostate, and colon and rectum [colorectum]) and in two major cancer sites in women (breast and colorectum). Overall cancer death rates decreased in men by 19.2% between 1990 and 2005, with decreases in lung (37%), prostate (24%), and colorectal (17%) cancer rates accounting for nearly 80% of the total decrease. Among women, overall cancer death rates between 1991 and 2005 decreased by 11.4%, with decreases in breast (37%) and colorectal (24%) cancer rates accounting for 60% of the total decrease. The reduction in the overall cancer death rates has resulted in the avoidance of about 650,000 deaths from cancer over the 15-year period. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, education, geographic area, and calendar year. Although progress has been made in reducing incidence and mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons younger than 85 years of age. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population and by supporting new discoveries in cancer prevention, early detection, and treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19474385     DOI: 10.3322/caac.20006

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  2000 in total

1.  Selenium-containing histone deacetylase inhibitors for melanoma management.

Authors:  Raghavendra Gowda; Subbarao V Madhunapantula; Dhimant Desai; Shantu Amin; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2012-06-06       Impact factor: 4.742

2.  Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI.

Authors:  B Nicolas Bloch; Elizabeth M Genega; Daniel N Costa; Ivan Pedrosa; Martin P Smith; Herbert Y Kressel; Long Ngo; Martin G Sanda; William C Dewolf; Neil M Rofsky
Journal:  Eur Radiol       Date:  2012-06-03       Impact factor: 5.315

3.  A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival.

Authors:  Jason A Willis; Sara H Olson; Irene Orlow; Semanti Mukherjee; Robert R McWilliams; Robert C Kurtz; Robert J Klein
Journal:  Clin Cancer Res       Date:  2012-06-04       Impact factor: 12.531

4.  A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer.

Authors:  Gregory M M Videtic; Chandana A Reddy; Lisa Sorenson
Journal:  Support Care Cancer       Date:  2012-06-02       Impact factor: 3.603

5.  Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

Authors:  Weijing Sun; Mark Powell; Peter J O'Dwyer; Paul Catalano; Rafat H Ansari; Al B Benson
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

6.  BRMS1 transcriptional repression correlates with CpG island methylation and advanced pathological stage in non-small cell lung cancer.

Authors:  Alykhan S Nagji; Yuan Liu; Edward B Stelow; George J Stukenborg; David R Jones
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

7.  Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling.

Authors:  Manjinder Kaur; Balaiya Velmurugan; Alpna Tyagi; Chapla Agarwal; Rana P Singh; Rajesh Agarwal
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

Review 8.  Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature.

Authors:  Giuliano M Bedoschi; Felipe Oliveira de Albuquerque; Rui Alberto Ferriani; Paula Andrea Navarro
Journal:  J Assist Reprod Genet       Date:  2010-05-09       Impact factor: 3.412

Review 9.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

10.  Role of pain medications, consultants, and other services in improved pain control of elderly adults with cancer in geriatric evaluation and management units.

Authors:  Ryan Nipp; Richard Sloane; Arati V Rao; Kenneth E Schmader; Harvey J Cohen
Journal:  J Am Geriatr Soc       Date:  2012-10-04       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.